Allogene’s TurboCAR ALLO-605 Receives Fast Track Designation From the FDA
On Wednesday, June 30, Allogene announced (press release) that the FDA has granted Fast Track designation to ALLO-605 (allogeneic BCMA TurboCAR) for r/r MM. Furthermore, management noted that ALLO-605’s Ph1 IGNITE trial was initiated in Q2 2021. Below, Celltelligence provides insights on how ALLO-605 could benefit from Fast Track designation while discussing Allogene’s TurboCAR program.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.